期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 72, 期 22, 页码 2761-2777出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.08.2200
关键词
aortic valve replacement; pulmonary autograft; Ross procedure; young adults
资金
- Abbott
- Cleveland Clinic
- Duke Clinical Research Institute
- Mayo Clinic
- Mount Sinai School of Medicine
- Population Health Research Institute
- Boehringer Ingelheim
- Amarin
- Amgen
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Chiesi
- Eisai
- Ethicon
- Forest Laboratories
- Idorsia
- Ironwood
- Ischemix
- Lilly
- Medtronic
- PhaseBio
- Pfizer
- Regeneron
- Roche
- Sanofi
- Synaptic
- Medicines Company
The ideal aortic valve substitute for young and middle-aged adults remains elusive. The Ross procedure (pulmonary autograft replacement) is the only operation that allows replacement of the diseased aortic valve with a living substitute. However, use of this procedure has declined significantly due to concerns over increased surgical risk and potential longterm failure of the operation. Several recent publications from expert centers have shown that in the current era, the Ross procedure can be performed safely and reproducibly in appropriately selected patients. Furthermore, an increasing body of evidence suggests that the Ross procedure is associated with better long-term outcomes compared with conventional aortic valve replacement in young and middle-aged adults. In this paper, the authors review the indications and technical considerations of the Ross procedure, describe its advantages and drawbacks, and discuss patient selection criteria. Finally, the authors provide a comprehensive synthesis of the current Ross published reports to enable cardiologists and surgeons to make appropriate decisions for their patients with aortic valve disease. (c) 2018 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据